Incidence and impact of immune combination therapies adverse events in advanced renal cell carcinoma patients
AEs are common in ICI-based therapies for RCC. While they do not negatively affect survival, their management, especially through dose reductions or steroids, may improve outcomes.
Authors
- Giulia Venturi (ORCID: https://orcid.org/0000-0002-1624-8946)
- Martina Catalano (ORCID: https://orcid.org/0000-0003-1856-2848)
- Luca Galli (ORCID: https://orcid.org/0000-0001-6008-0266)
- Giandomenico Roviello (ORCID: https://orcid.org/0000-0001-5504-8237)
- Laura Doni
- Alessia Salfi
- Federico Paolieri (ORCID: https://orcid.org/0009-0009-6533-6449)
- Michele Sisani
- Francesco Bloise
Institutions
- Azienda Ospedaliero-Universitaria Careggi (IT)
- Ospedale San Donato (IT)
- Azienda Usl Toscana Centro (IT)
- Azienda Ospedaliera Universitaria Pisana (IT)
- Hospital of Prato (IT)
- University of Florence (IT)
Publication Details
- Journal
- Immunotherapy
- Published
- 2025-03-04
- DOI
- https://doi.org/10.1080/1750743x.2025.2482510
- Citations
- 2
- Primary Topic
- Renal cell carcinoma treatment
- Type
- article
- Field-Weighted Citation Impact
- 3.04